[BORA] Subsidiary TWi Pharmaceuticals USA, Inc. Announces Filing Pursuant to Article 22, Paragraph 1, Item 3 of the "Regulations Governing the Handling of Loans and Endorsements and Guarantees by Publicly Issued Companies"

1. Date of event: 115/06/10 2. Recipient of funds: (1) Company Name: Upsher-Smith Laboratories, LLC (2) Relationship with the company lending funds: An indirectly wholly-owned subsidiary of the Company (loaned by subsidiary TWi Pharmaceuticals USA, Inc.) (3) Limit of loan (in thousands of NT$): 2,445,610 (4) Balance of original loan (in thousands of NT$): 767,248 (5) Amount of new loan this time (in thousands of NT$): 411,710 (6) Is this a loan authorized by the board of directors for the chairman to lend or revolve to the same borrower in installments: No (7) Balance of loan as of the date of the event (in thousands of NT$): 1,178,958 (8) Reason for the new loan this time: To supplement working capital 3. Collateral provided by the company receiving the loan: (1) Content: None (2) Value (in thousands of NT$): 0 4. Most recent financial statements of the company receiving the loan: (1) Capital (in thousands of NT$): 31,433,941 (2) Accumulated profit or loss (in thousands of NT$): -24,416,454 5. Interest calculation method: As stipulated in the contract 6. Repayment: (1) Conditions: The loan period is one year, and early repayment is possible. (2) Date: The loan period is one year, and early repayment is possible. 7. Loan balance as of the date of the event (in thousands of NT$): 1,178,958 8. Ratio of loan balance as of the date of the event to the net worth of the publicly issued company's most recent financial statements: 8.09 9. Source of funds lent by the company to others: Subsidiary itself 10. Other matters to be stated: Calculated using an exchange rate of USD to NT$ 31.67